Showing 7961-7970 of 8465 results for "".
- Chromogenex Releases Regenlite Transformhttps://practicaldermatology.com/news/chromogenex-releases-regenlite-transform/2459042/The latest addition to the Chromogenex family, Regenlite Transform is now available. It is specifically designed for managing inflammatory skin conditions without any discomfort, downtime or residual cell necrosis, the company says. A pure 585nm laser offers 300% more absorption in Oxyhae
- ArteFill Changes Name to Bellafillhttps://practicaldermatology.com/news/artefill-changes-name-to-bellafill/2459051/Suneva Medical, Inc.’s ArteFill dermal filler has been rebranded as Bellafill in the US. "We feel that the brand Bellafill better embodies the transformational outcomes this unique product can provide to our customers and th
- DermSpectra Releases Total Body Digital Skin Imaging Systemhttps://practicaldermatology.com/news/dermspectra-releases-its-total-body-digital-skin-imaging-system/2459052/DermSpectra realease its DermSpectra Total Body Digital Skin Imaging System, which enables physicians to monitor critical skin changes (skin cancers, eczema, lesions, psoriasis, and rashes) over time. The DermSpectra advanced medical technology allows physicians to digitally capture and compare s
- FDA Approves Valeant's Onexton Gel for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-valeants-onexton-gel-for-the-treatment-of-acne-vulgaris/2459053/The FDA approved Valeant Pharmaceuticals International, Inc.’s Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new d
- PV-10 Data Published; Phase 3 Protocol Publishedhttps://practicaldermatology.com/news/20141121-pv-10_data_published_phase_3_protocol_published/2459054/Phase II data for PV-10 (Provectus Biopharmaceuticals, Inc.), presented at scientific meetings this fall, were published in Annals of Surgical Oncology in October. In the 80-subject study, the best overall response rate for target lesions was 51 percent, and the complete response rate was 26 percent
- Galderma Partners with AARS in Support of CDC's "Get Smart About Antibiotics Week"https://practicaldermatology.com/news/20141121-galderma_partners_with_aars_in_support_of_cdcs_get_smart_about_antibiotics_week/2459055/Galderma Laboratories, L.P. joined the American Acne and Rosacea Society (AARS) and the Centers for Disease Control and Prevention's (CDC) Get Smart About Antibiotics Week 2014 (November 17 – 23). AARS and Galderma Laboratories, the first dermatology partner to join with AARS on the initiative, are
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi
- Michael R. Stewart Named Next President and CEO of MELA Scienceshttps://practicaldermatology.com/news/20141119-micheal_r_stewart_named_next_president_and_ceo_of_mela_sciences/2459057/MELA Sciences, Inc. developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, announced that its Board of Directors has named Michael R. Stewart, 57, as the company's n
- Gabrielle Rios, Founder of TruInject, Wins Stevie Award for Startupshttps://practicaldermatology.com/news/20141119-gabrielle_rios_founder_of_truinject_wins_stevie_award_for_startups/2459058/Gabrielle Rios, chief executive officer of TruInject Medical Corporation, received the Bronze Award at the 2014 Stevie Awards for Women in Business. The award was presented in the category of Startup of the Year. The Stevie® Awards for Women in Business honors women executives, entrepreneurs, a
- Valeant Comments On Allergan Announcementhttps://practicaldermatology.com/news/20141117-valeant_comments_on_allergan_announcement/2459060/Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock. "We have seen the annou